Abcam, ab250271, Anti-CBR3 antibody [EPR14129] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CBR3 antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14129,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250271 is the carrier-free version of
ab180939
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The enzyme carbonyl reductase 3 commonly known as CBR3 is a member of the short-chain dehydrogenase/reductase superfamily. With a molecular mass of approximately 31 kDa CBR3 catalyzes the reduction of carbonyl compounds into alcohols using NADPH as a cofactor. It is expressed in various tissues including liver kidney and heart where it plays a role in xenobiotic metabolism and the detoxification processes by reducing carbonyl-containing compounds.
Biological function summary
CBR3 operates as a critical component in enzymatic systems that protect against oxidative stress. It reduces reactive carbonyls derived from lipid peroxidation products contributing to cellular antioxidant defenses. Although not typically recognized as part of a large complex its activity often synergizes with other reductases and dehydrogenases in these protective roles. This activity helps to limit the damage from lipid peroxidation and therefore maintain cellular function under oxidative stress conditions.
Pathways
CBR3 plays a significant part in the drug metabolism pathway where it metabolizes various therapeutic drugs and environmental toxins. The enzyme interacts closely with NADPH-dependent cofactors and other reductases like CBR1 facilitating phase I detoxification processes. Additionally CBR3 contributes to the prostaglandin synthesis pathway by converting prostaglandin E2 into less active forms interacting relevantly with enzymes involved in prostaglandin metabolism.
CBR3 has been linked to anthracycline-induced cardiotoxicity and certain forms of cancer. In cardiac tissues CBR3 expression influences susceptibility to damage caused by anthracycline antibiotics which are commonly used in cancer chemotherapy. Variations in the gene encoding CBR3 affect the metabolism and clearance of these drugs potentially exacerbating cardiac damage. In cancer CBR3 along with proteins like CBR1 modulates susceptibility to chemotherapeutic agents impacting drug efficacy and toxicity. Understanding the polymorphisms of CBR3 may optimize therapeutic strategies and prevent adverse effects in susceptible individuals.